Guardant Health, Inc.(GH)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Guardant Health, Inc. (GH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GH at 39.0/100 on a 32-signal composite quality model, placing it at rank #2,164 of 2,961 stocks — the bottom half of the AI-ranked universe. GH scores in the top quartile across revenue growth (90.6). Areas of concern include balance sheet strength (8.3) and free cash flow (12.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Guardant Health, Inc. reports quarterly revenue of $335.0M, net income of $-120.1M, an operating margin of -38.6%. Top institutional holders of GH by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GH trades on the Nasdaq exchange and files with the SEC under CIK 1576280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardant Health, Inc. directly from SEC EDGAR.

AI Quality Score

39.0/100

AI Rank

#2,164

Revenue

$335.0M

Net Income

$-120.1M

Free Cash Flow

$-69.5M

Operating Margin

-38.6%

GH key financials by period

Guardant Health, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$982.0M$-416.3M-44.5%
FY 202410-K$739.0M$-436.4M-60.0%
FY 202310-K$563.9M$-479.4M-100.1%
FY 202210-K$449.5M$-654.6M-121.1%
FY 202110-K$373.7M$-384.8M-110.0%
FY 202010-K$286.7M-88.9%

Institutions holding GH

Institutional investors reporting a position in Guardant Health, Inc. on SEC Form 13F.
InstitutionSharesValueReported
BlackRock7,622,935$1.1B2026-06-30
PRICE T ROWE ASSOCIATES6,514,952$977.4M2026-06-30
VANGUARD CAPITAL MANAGEMENT5,755,857$863.6M2026-06-30
FMR5,488,272$823.4M2026-06-30
VANGUARD PORTFOLIO MANAGEMENT5,445,785$817.0M2026-06-30
Invesco Ltd.4,429,755$664.6M2026-06-30
GOLDMAN SACHS GROUP3,775,895$566.5M2026-06-30
TWO SIGMA INVESTMENTS3,719,301$558.0M2026-06-30
LINDEN ADVISORS204,330,000$514.2M2026-06-30
Capital International Investors3,399,604$510.0M2026-06-30
GH

Guardant Health, Inc.

GH
NasdaqLarge CapHealthcare

13F Pro Quality Score

39.0/100

Rank #2,164 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

90.6/100

Profitability

13.1/100

Balance Sheet

8.3/100

Earnings Quality

36.5/100

Free Cash Flow

12.7/100

Institutional Flow

46.8/100

Revenue Scale

53.2/100

Dilution Risk

10.7/100

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$334.98M

Net Income

Q2 2026
EDGAR

$-120.14M

EPS (Diluted)

Q2 2026
EDGAR

$-0.90

Operating Margin

Q2 2026
EDGAR

-38.6%

ROIC

Q2 2026
EDGAR

-40.4%

Free Cash Flow

Q2 2026
EDGAR

$-69.54M

Top Institutional Holders

as of Q2 2026
$22.43B total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…